AroCell AB (publ) (AROC.ST)
SEK 0.38
(-4.98%)
SEK 0.38
(-4.98%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 174.89 Million SEK | -25.9% |
| 2022 | 236.01 Million SEK | 3.78% |
| 2021 | 227.41 Million SEK | 276.04% |
| 2020 | 60.47 Million SEK | -33.81% |
| 2019 | 91.37 Million SEK | 59.14% |
| 2018 | 57.41 Million SEK | 15.96% |
| 2017 | 49.51 Million SEK | -25.45% |
| 2016 | 66.42 Million SEK | -10.63% |
| 2015 | 74.32 Million SEK | 92.54% |
| 2014 | 38.6 Million SEK | 113.92% |
| 2013 | 18.04 Million SEK | 50.63% |
| 2012 | 11.98 Million SEK | 70.76% |
| 2011 | 7.01 Million SEK | 92.75% |
| 2010 | 3.63 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 164.54 Million SEK | -5.92% |
| 2024 Q2 | 152.88 Million SEK | -7.09% |
| 2024 Q3 | 143.25 Million SEK | -6.3% |
| 2023 Q4 | 174.89 Million SEK | -8.64% |
| 2023 FY | 174.89 Million SEK | -25.9% |
| 2023 Q3 | 191.42 Million SEK | -6.41% |
| 2023 Q2 | 204.52 Million SEK | -7.33% |
| 2023 Q1 | 220.7 Million SEK | -6.49% |
| 2022 Q4 | 236.01 Million SEK | -5.32% |
| 2022 FY | 236.01 Million SEK | 3.78% |
| 2022 Q3 | 249.28 Million SEK | -5.42% |
| 2022 Q2 | 263.58 Million SEK | -10.7% |
| 2022 Q1 | 295.15 Million SEK | 29.79% |
| 2021 Q1 | 53.9 Million SEK | -10.87% |
| 2021 Q4 | 227.41 Million SEK | -8.12% |
| 2021 Q2 | 48.78 Million SEK | -9.5% |
| 2021 Q3 | 247.5 Million SEK | 407.36% |
| 2021 FY | 227.41 Million SEK | 276.04% |
| 2020 Q2 | 72.55 Million SEK | -7.16% |
| 2020 Q1 | 78.15 Million SEK | -14.47% |
| 2020 FY | 60.47 Million SEK | -33.81% |
| 2020 Q3 | 65.84 Million SEK | -9.26% |
| 2020 Q4 | 60.47 Million SEK | -8.15% |
| 2019 Q3 | 43.54 Million SEK | -6.95% |
| 2019 Q4 | 91.37 Million SEK | 109.85% |
| 2019 Q2 | 46.79 Million SEK | -9.4% |
| 2019 Q1 | 51.65 Million SEK | -10.04% |
| 2019 FY | 91.37 Million SEK | 59.14% |
| 2018 Q2 | 68.44 Million SEK | 48.72% |
| 2018 FY | 57.41 Million SEK | 15.96% |
| 2018 Q4 | 57.41 Million SEK | -8.19% |
| 2018 Q3 | 62.53 Million SEK | -8.62% |
| 2018 Q1 | 46.02 Million SEK | -7.06% |
| 2017 Q4 | 49.51 Million SEK | -8.0% |
| 2017 FY | 49.51 Million SEK | -25.45% |
| 2017 Q1 | 61.46 Million SEK | -7.46% |
| 2017 Q2 | 59.18 Million SEK | -3.72% |
| 2017 Q3 | 53.82 Million SEK | -9.06% |
| 2016 FY | 66.42 Million SEK | -10.63% |
| 2016 Q1 | 71.94 Million SEK | -3.2% |
| 2016 Q4 | 66.42 Million SEK | -5.07% |
| 2016 Q3 | 69.96 Million SEK | -1.63% |
| 2016 Q2 | 71.12 Million SEK | -1.14% |
| 2015 Q3 | 33.25 Million SEK | -2.5% |
| 2015 FY | 74.32 Million SEK | 92.54% |
| 2015 Q4 | 74.32 Million SEK | 123.51% |
| 2015 Q1 | 34.6 Million SEK | -10.37% |
| 2015 Q2 | 34.1 Million SEK | -1.44% |
| 2014 Q4 | 38.6 Million SEK | 72.25% |
| 2014 Q3 | 22.41 Million SEK | -2.47% |
| 2014 FY | 38.6 Million SEK | 113.92% |
| 2014 Q2 | 22.97 Million SEK | -6.0% |
| 2014 Q1 | 24.44 Million SEK | 35.47% |
| 2013 Q3 | 16.25 Million SEK | -7.01% |
| 2013 Q4 | 18.04 Million SEK | 11.03% |
| 2013 FY | 18.04 Million SEK | 50.63% |
| 2013 Q1 | 11.06 Million SEK | -7.64% |
| 2013 Q2 | 17.47 Million SEK | 57.96% |
| 2012 Q4 | 11.98 Million SEK | 32.77% |
| 2012 Q3 | 9.02 Million SEK | -1.56% |
| 2012 Q1 | 6.51 Million SEK | -7.16% |
| 2012 FY | 11.98 Million SEK | 70.76% |
| 2012 Q2 | 9.16 Million SEK | 40.73% |
| 2011 FY | 7.01 Million SEK | 92.75% |
| 2011 Q4 | 7.01 Million SEK | -17.89% |
| 2011 Q3 | 8.54 Million SEK | -8.01% |
| 2011 Q2 | 9.28 Million SEK | 0.0% |
| 2010 Q4 | 3.63 Million SEK | 0.0% |
| 2010 FY | 3.63 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Devyser Diagnostics AB (publ) | 510.1 Million SEK | 65.714% |
| Immunovia AB (publ) | 98.68 Million SEK | -77.23% |
| Prostatype Genomics AB (publ) | 49.22 Million SEK | -255.313% |
| SenzaGen AB | 97.17 Million SEK | -79.974% |
| Spermosens AB | 26.1 Million SEK | -569.956% |